news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

on september 5, the national health insurance administration announced a list of 28 companies rated as "particularly serious" and "serious" dishonest by various provinces as of june 30, 2024. among them,four companies including sichuan beijukang medical equipment co., ltd. and sichuan runzeyuan medical equipment co., ltd. were rated as "particularly serious"according to the regulations, all the online listing, bidding or distribution qualifications of such enterprises for all drugs and medical consumables are suspended, and the suspension period is subject to the pharmaceutical enterprises' credit restoration and rating results change.

five new companies have been added to the list, namelybeijing tongrentang (bozhou) pieces co., ltd., shanxi zhendong authentic medicinal materials development co., ltd., anguo putianhe chinese medicine pieces co., ltd., anhui fengliaoxing chinese medicine pieces co., ltd. and jiangsu kangsheng pharmaceutical co., ltd.,it was rated as a "serious" dishonest enterprise in shandong and jiangsu provinces respectively.

price procurement credit ratings are generally assessed based on the severity of the amount of bribes paid by the company, improper pricing behavior, and disruption of centralized purchasing order.the newly added four companies, including beijing tongrentang (bozhou) pieces co., ltd., are allselected companies with supply problems in the inter-provincial alliance procurement of chinese herbal medicines, they were originally responsible for supplying varieties with large clinical usage, such as yam, atractylodes, peony, and licorice tablets. according to the shandong provincial public resources trading center, after winning the joint procurement bid, these companies refused to fulfill their commitments and refused to fulfill the purchase and sales or distribution contracts without proper reasons. in december last year, the qualifications of a total of 9 companies, including the above 4 companies, were cancelled by shandong province. another 5 companies, such as kangmei pharmaceutical co., ltd. and chengdu kangmei pharmaceutical production co., ltd., were also rated as "general" dishonest companies.

according to the documentation,the serious dishonesty of four companies including beijing tong ren tang (bozhou) pieces co., ltd. will be maintained for three years.until december 20, 2026. according to the regulations, in addition to warnings and risk alerts, pharmaceutical companies that "seriously" breach their trust should be suspended from listing, bidding or distribution of the products involved in the case, and the suspension period will be based on their credit repair and grade changes.

north china pharmaceutical was once again named in the list of dishonest persons.in the third batch of national centralized procurement, north china pharmaceutical won the bid for ibuprofen sustained-release capsules and was responsible for the supply to seven provinces including tianjin, shanxi, shandong, hubei, and hunan. at that time, north china pharmaceutical's offer was not low, with an average price of about 0.27 yuan per 0.3g capsule. however, north china pharmaceutical did not supply the agreed supply volume when fulfilling the contract, and after multiple talks and consultations with relevant departments, the supply situation has not improved.

finally, in august 2021, north china pharmaceutical announced its withdrawal from the bid and was rated as a "serious" dishonest enterprise by shandong province.three years later, north china pharmaceutical is still on the list of “serious” dishonest companies.

credit ratings are not irrecoverable. according to the relevant provisions of the "operational specifications for pharmaceutical price and procurement credit ratings" and the "discretionary criteria for pharmaceutical price and procurement credit ratings", if the duration of dishonesty exceeds 3 years, the dishonesty information will be retained but will no longer be used as the basis for credit rating. the health bureau has sorted out and found that since the national medical insurance administration released the first phase of the price and procurement credit rating dishonesty assessment results,a total of 43 companies were on the list of dishonest companies, and 15 of them have restored their credit.companies that were listed as seriously dishonest during the same period as north china pharmaceutical, such as yuheng pharmaceutical and renfu pharmaceutical, were listed due to commercial bribery, and their credit ratings have been restored.

according to relevant regulations, if there are dishonest behaviors, such as commercial bribery, tax violations, price monopoly, etc., pharmaceutical companies can also take the initiative to take remedial measures to repair their credit ratings, such as publicly apologizing to eliminate adverse effects and proactively eliminating the inflated space in the prices of the products involved.enterprises that have committed illegal bidding and breach of promises and have been rated as "serious" in breach of trust will not be accepted for voluntary repair.

written by yang xixia

editor: jiang yunjiating

operation｜twenty thirteen

illustration｜visual china

disclaimer: this is original content from jianshiju. please do not reprint without permission.

the audit department joined in to dig deep into the production and sales of many public hospitals and pharmaceutical equipment

the deputy secretary of a well-established top three hospital was dismissed and was in charge of the hospital's information construction

new news丨up to 635 million us dollars! another double-antibody successfully launched overseas